Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully delivered the second preclinical candidate compound (PCC) in its collaboration with Fosun Pharma in June 2024, a potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors.
Research suggests booster doses may be necessary for monkeypox immunity
New research to be presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) in Barcelona, Spain (27-30 April) shows that